Industry Events
EnglishFrançaisEspañol中文العربية
活动新闻行业洞察主办方
服务
  • 活动营销向全球B2B受众发布、推广并拓展您的活动。
  • 新闻稿向全球行业专业人士分发官方公告。
  • 演讲者与专家推广展示您的专业知识,获得主旨演讲、专题讨论和大师班邀约。
订阅
演讲者登录免费发布您的活动
Industry Events

全球最值得信赖的B2B活动发现平台。将行业专业人士与重要的会议、展会和峰会连接起来。

  • Industry Events
  • 新闻
  • 活动主办方
  • 关于我们
  • 我们的服务
  • 高级主办方
  • Event Pro
  • 成为演讲者
  • 订阅
  • 使用条款
  • 隐私政策

© 2026 Industry Events Worldwide。保留所有权利。

VF96.7.
  • 活动
  • 新闻
  • 行业洞察
  • 账户
Industry Events
EnglishFrançaisEspañol中文العربية
活动新闻行业洞察主办方
服务
  • 活动营销向全球B2B受众发布、推广并拓展您的活动。
  • 新闻稿向全球行业专业人士分发官方公告。
  • 演讲者与专家推广展示您的专业知识,获得主旨演讲、专题讨论和大师班邀约。
订阅
演讲者登录免费发布您的活动
Industry Events

News

Categories

  • 最新
  • 中国与金砖国家+
  • 人工智能与科技
  • 供应链
  • 农业
  • 创业与风险投资
  • 医疗健康
  • 半导体
  • 国防
  • 机器人
  • 网络安全
  • 能源与出行
  • 金融科技

Select a category to explore the latest industry reporting.

NewsTuesday, 25 August 2026
Newsletter subscribe · Free
  • 最新
  • 人工智能与科技
  • 网络安全
  • 半导体
  • 机器人
  • 金融科技
  • 能源与出行
  • 国防
  • 医疗健康
  • 供应链
  • 创业与风险投资
  • 中国与金砖国家+
  • 农业

新闻

医疗健康

来自塑造行业的会议、展会和峰会的 医疗健康 领域最新新闻、公告和分析。

该分类的最新新闻

STAT+: Pharmalittle: We’re reading about a setback for Eyepoint, a win for Amylyx, and more (opens original source in a new tab)
STAT News

STAT+: Pharmalittle: We’re reading about a setback for Eyepoint, a win for Amylyx, and more

Industry Events

全球最值得信赖的B2B活动发现平台。将行业专业人士与重要的会议、展会和峰会连接起来。

Eyepoint disclosed that a Phase 3 trial of its experimental treatment for a common cause of age-related blindness fell short of its primary goal

(opens original source in a new tab)
Ed Silverman·18 August 2026
STAT+: Sanofi to lay off 229 workers in Mass., a year after $9.1B Blueprint Medicines acquisition (opens original source in a new tab)
STAT News

STAT+: Sanofi to lay off 229 workers in Mass., a year after $9.1B Blueprint Medicines acquisition

Sanofi, one of the Massachusetts' largest pharmaceutical employers, will lay off more than 200 workers there a year after acquiring Blueprint Medicines.

(opens original source in a new tab)
Auzzy Byrdsell — Boston Globe·17 August 2026
STAT+: Eyepoint study results for vision treatment disappoint, but company still sees promise (opens original source in a new tab)
STAT News

STAT+: Eyepoint study results for vision treatment disappoint, but company still sees promise

Eyepoint said patients given its experimental treatment for wet AMD failed to maintain vision with less frequent injections compared to a standard treatment.

(opens original source in a new tab)
Adam Feuerstein·17 August 2026
STAT+: The IRS is probing UnitedHealth, and a private equity slowdown (opens original source in a new tab)
STAT News

STAT+: The IRS is probing UnitedHealth, and a private equity slowdown

UnitedHealth faces an investigation over tax payments, and we examine why PE deals for doctor groups are slowing.

(opens original source in a new tab)
Bob Herman·17 August 2026
STAT+: Akeso and Summit’s lung cancer drug shows worsening tumor-progression benefit (opens original source in a new tab)
STAT News

STAT+: Akeso and Summit’s lung cancer drug shows worsening tumor-progression benefit

Europe pulls Tavneos over trial integrity concerns, pricing concerns over AstraZeneca's hypertension drug, and more biotech news from The Readout

(opens original source in a new tab)
Meghana Keshavan·17 August 2026
STAT+: Pharmalittle: We’re reading about an AstraZeneca setback, falling U.S. drug prices, and more (opens original source in a new tab)
STAT News

STAT+: Pharmalittle: We’re reading about an AstraZeneca setback, falling U.S. drug prices, and more

AstraZeneca is discontinuing a late-stage drug trial in patients with metastatic non-small cell lung cancer, extending a run of setbacks

(opens original source in a new tab)
Ed Silverman·17 August 2026
Everything the Trump administration did on health care last week (opens original source in a new tab)
STAT News

Everything the Trump administration did on health care last week

An executive order remaking the federal vaccine agenda, Epic's antitrust lawsuits, and more health news from Morning Rounds

(opens original source in a new tab)
Theresa Gaffney·17 August 2026
Opinion: We proved bipartisan health care reform works in North Carolina. Let’s bring it nationwide (opens original source in a new tab)
STAT News

Opinion: We proved bipartisan health care reform works in North Carolina. Let’s bring it nationwide

“North Carolina proved that pragmatism can beat partisanship,” write Mandy Cohen and Kody Kinsley.

(opens original source in a new tab)
Mandy Cohen and Kody Kinsley·17 August 2026
STAT+: Epic confronts unprecedented challenges as it prepares to address customers and unveil road map (opens original source in a new tab)
STAT News

STAT+: Epic confronts unprecedented challenges as it prepares to address customers and unveil road map

Epic, whose software is used by the majority of American hospitals, faces unprecedented challenges ahead of its annual User Group Meeting.

(opens original source in a new tab)
Brittany Trang and Casey Ross·17 August 2026
STAT+: UnitedHealth faces IRS probe over potential tax avoidance (opens original source in a new tab)
STAT News

STAT+: UnitedHealth faces IRS probe over potential tax avoidance

The health insurer may face a significant increase in taxes, amid a dispute with federal authorities.

(opens original source in a new tab)
Bob Herman·17 August 2026
STAT+: Kennedy’s split-screen week: Talk of vaccines in D.C., fraud and addiction out West (opens original source in a new tab)
STAT News

STAT+: Kennedy’s split-screen week: Talk of vaccines in D.C., fraud and addiction out West

The California trip shows how Kennedy likes to focus on key MAHA themes, while avoiding some divisive topics.

(opens original source in a new tab)
Chelsea Cirruzzo·17 August 2026
STAT+: State laws may be curbing private equity takeovers of physician group (opens original source in a new tab)
STAT News

STAT+: State laws may be curbing private equity takeovers of physician group

Private equity deals for practice management firms are declining sharply.

(opens original source in a new tab)
Tara Bannow·17 August 2026

最多阅读

  1. 01

    STAT+: Pharmalittle: We’re reading about a setback for Eyepoint, a win for Amylyx, and more

  2. 02

    STAT+: Sanofi to lay off 229 workers in Mass., a year after $9.1B Blueprint Medicines acquisition

  3. 03

    STAT+: Eyepoint study results for vision treatment disappoint, but company still sees promise

  4. 04

    STAT+: The IRS is probing UnitedHealth, and a private equity slowdown

  5. 05

    STAT+: Akeso and Summit’s lung cancer drug shows worsening tumor-progression benefit

Prev
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
Next
  • Industry Events
  • 新闻
  • 活动主办方
  • 关于我们
  • 我们的服务
  • 高级主办方
  • Event Pro
  • 成为演讲者
  • 订阅
  • 使用条款
  • 隐私政策

© 2026 Industry Events Worldwide。保留所有权利。

VF96.7.

每周五送达的行业活动一周要闻。

一封简短的邮件。汇集塑造全球商业的展会、会议和峰会的头条新闻。没有废话,没有垃圾邮件,随时可取消订阅。